SIREN : 351440177
SABLE INJECTION is a French company founded 36 years ago, specialized in the sector Fabrication d'autres équipements automobiles. Based in SABLE-SUR-SARTHE (72300), this company of category ETI shows in 2024 a revenue of 12.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12 310 028 € | 19 017 420 € | 16 710 723 € | 13 907 153 € | 11 888 658 € | 15 794 980 € | 12 206 013 € | 11 825 261 € | 10 204 896 € |
| Net income | -50 082 € | 474 810 € | 422 029 € | 345 633 € | 922 € | 464 273 € | 452 709 € | 741 525 € | 596 643 € |
| EBITDA | 157 601 € | 1 337 232 € | 1 074 936 € | 1 433 501 € | 686 388 € | 814 434 € | 664 851 € | 1 137 971 € | 1 014 968 € |
| Net margin | -0.4% | 2.5% | 2.5% | 2.5% | 0.0% | 2.9% | 3.7% | 6.3% | 5.8% |
In 2024, SABLE INJECTION achieves revenue of 12.3 M€. Revenue is growing positively over 9 years (CAGR: +2.4%). Significant drop of -35% vs 2023. After deducting consumption (5.2 M€), gross margin stands at 7.1 M€, i.e. a rate of 58%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 158 k€, representing 1.3% of revenue. Warning negative scissor effect: despite revenue change (-35%), EBITDA varies by -88%, reducing margin by 5.8 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Net income is negative at -50 k€ (-0.4% of revenue), which will impact equity.
12 310 028 €
7 124 851 €
157 601 €
-169 750 €
-50 082 €
1.3%
The debt ratio (= Financial debt / Equity x 100) stands at 91%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 30%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 18.9 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 0.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
91.028%
29.926%
0.914%
18.894
32.7%
In 2024, the debt ratio of SABLE INJECTION (91.03) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of SABLE INJECTION (29.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of SABLE INJECTION (18.89) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 129.18. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 53.7x. Operating income very largely covers interest expenses: high safety margin.
129.18
53.727
In 2024, the liquidity ratio of SABLE INJECTION (129.18) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of SABLE INJECTION (53.7x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 82 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 70 days. The company must finance 12 days of gap between collections and payments. Inventory turnover is 33 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 90 days of revenue, i.e. 3.1 M€ to permanently finance.
3 087 232 €
82 j
70 j
33 j
90 j
Indicative estimate only : the number of comparable transactions in this sector is limited (22 transactions). This range of 3 575 834€ to 7 616 402€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 22 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SABLE INJECTION with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication d'autres équipements automobiles
The revenue of SABLE INJECTION in 2024 is 12.3 M€.
SABLE INJECTION recorded a net loss in 2024.
The headquarters of SABLE INJECTION is located in SABLE-SUR-SARTHE (72300), in the department Sarthe.
The tax return of SABLE INJECTION is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SABLE INJECTION operates in the sector Fabrication d'autres équipements automobiles (NAF code 29.32Z). See the 'Sector positioning' section above to compare the company with its competitors.